News from Friday, July 25, 2025
Articles
Cardiovascular Risks Resurface Old Concerns About Sulfonylureas for T2D
(7/24, Nicole Lou, Medpage Today) reports “...Sulfonylureas were flagged for excess cardiovascular risk when used for additional glucose lowering in type 2 diabetes (T2D) in an observational comparative effectiveness study. As second-line therapies atop metformin, individual sulfonylureas were associated with cardiovascular risk estimates that trended numerically, if not significantly, in the wrong direction when compared with DPP4 inhibitors, according to researchers led by Alexander Turchin, MD, MS, of Brigham and Women's Hospital in Boston.” Full
Ustekinumab Shows Promise Over Anti-TNF Therapy in Treating CLDP
(7/25, Jessica Nye, PhD, Rheumatology Advisor) reports “Ustekinumab may be more effective than anti-tumor necrosis factor (anti-TNF) therapies in achieving clinical remission among patients with Crohn-like disease of the pouch (CLDP), according to study results published in the American Journal of Gastroenterology.” Full
Realizing the Full Potential of Patient Engagement in Clinical Research
(7/24, Beverly Canin, The ASCO Post) comments “...One of the CARG co-leaders, Dr. Supriya Mohile, invited me to collaborate with her in developing a stakeholder advisory group for a study she was designing for a grant application to the Patient-Centered Outcomes Research Institute. It was called Communicating About Aging and Cancer Health, or COACH. It compared the effectiveness of providing a patient-reported geriatric assessment summary to patients, caregivers, and oncologists vs usual care in improving patient satisfaction with communication about age-related concerns during advanced cancer treatment.” Full
New PRI Brief Warns Trump Drug Price Control Policies Would Lead U.S. Down the Path to European-Style Socialism
(7/25, Sally Pipes, Wayne Winegarden, Pacific Research Institute) comments “...Drawing from Friedrich Hayek's famed warning about centralized economic planning, the brief cautions that free market supporters who endorse government price controls are embracing the same destructive socialist policies that destroyed Europe's pharmaceutical leadership.” Full
Press Releases
Study Compares Common Type 2 Diabetes Drugs, Finding Higher Cardiovascular Risk for One Medication
(7/24, Mass General Brigham Press Release) “...The study examined nationwide data from nearly 50,000 patients treated with different sulfonylureas and found that glipizide – the most widely used drug in the U.S. within this category – was linked to higher incidence of heart failure, related hospitalization and death compared to dipeptidyl peptidase-4 (DPP-4) inhibitors. Results are published in JAMA Network Open.” Full
Journals
Comparative Effectiveness of Porcine Placental Extracellular Matrix Against Other Cellular, Acellular and Matrix-Like Products in Diabetic Foot Ulcers from the Medicare Database
Brad Marcinek, et al.
July 25, 2025, Journal of Comparative Effectiveness Research
Comparative Effectiveness of Rehabilitation Therapies for Diastasis Recti Abdominis: A Systematic Review and Bayesian Network Meta-Analysis
Jiahui Zhu, et al.
July 25, 2025, International Journal of Gynaecology and Obstetrics
Global Research on Patient Involvement in Health Technology Assessment: A Bibliometric Analysis
Chunlu Yu, et al.
July 25, 2025, Global Health Research and Policy
Reports
The Rise—and Potential Fall—of America’s Drug Industry: How to Avoid the Road to Serfdom
July 2025